0001209191-22-001628.txt : 20220105 0001209191-22-001628.hdr.sgml : 20220105 20220105160430 ACCESSION NUMBER: 0001209191-22-001628 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220103 FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GEMAYEL GEORGES CENTRAL INDEX KEY: 0001256088 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39438 FILM NUMBER: 22511091 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gemini Therapeutics, Inc. /DE CENTRAL INDEX KEY: 0001816736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851613057 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (617) 401-4400 MAIL ADDRESS: STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: FS Development Corp. DATE OF NAME CHANGE: 20200702 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-03 0 0001816736 Gemini Therapeutics, Inc. /DE GMTX 0001256088 GEMAYEL GEORGES C/O GEMINI THERAPEUTICS, INC. NOT APPLICABLE DE 1 1 0 0 Executive Chair of the Board Stock Option (Right to Buy) 3.08 2022-01-03 4 A 0 793274 0.00 A 2032-01-02 Common Stock 793274 793274 D 50% of the Option Shares shall become exercisable on August 5, 2022 and the remaining 50% of the Option Shares shall become exercisable on August 5, 2023. /s/ Brian Piekos, attorney-in-fact 2022-01-05